SQZ Biotechnologies CoNYSE:SQZ
- LAST PRICE0.8200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7000/ 4
- Ask / Lots0.8220/ 8
- Open / Previous Close0.8400 / 0.8200
- Day Range
- 52 Week Range
- Volume112,892
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | SQZ |
|---|---|---|
| 09:32 ET | 2839 | 0.82 |
| 09:33 ET | 1119 | 0.8301 |
| 09:42 ET | 200 | 0.835001 |
| 09:44 ET | 1114 | 0.83 |
| 09:48 ET | 1200 | 0.86 |
| 10:09 ET | 100 | 0.835001 |
| 10:13 ET | 180 | 0.84 |
| 10:24 ET | 469 | 0.83 |
| 10:27 ET | 400 | 0.8301 |
| 10:36 ET | 100 | 0.83 |
| 11:00 ET | 1000 | 0.815 |
| 11:12 ET | 2000 | 0.8399 |
| 11:14 ET | 1000 | 0.84 |
| 11:16 ET | 6600 | 0.8505 |
| 11:23 ET | 1000 | 0.8436 |
| 11:38 ET | 2341 | 0.84 |
| 11:56 ET | 2000 | 0.84 |
| 12:03 ET | 1704 | 0.815 |
| 12:19 ET | 5244 | 0.8399 |
| 12:30 ET | 10000 | 0.8399 |
| 12:32 ET | 100 | 0.84 |
| 12:46 ET | 500 | 0.829501 |
| 12:48 ET | 115 | 0.8365 |
| 12:57 ET | 5000 | 0.83 |
| 01:13 ET | 1952 | 0.8205 |
| 01:18 ET | 1700 | 0.83 |
| 01:20 ET | 1400 | 0.83 |
| 01:22 ET | 200 | 0.83 |
| 01:24 ET | 714 | 0.83 |
| 01:26 ET | 1424 | 0.83 |
| 01:36 ET | 603 | 0.83 |
| 01:38 ET | 1318 | 0.83 |
| 01:42 ET | 5700 | 0.83 |
| 02:09 ET | 800 | 0.8299 |
| 02:12 ET | 1055 | 0.8101 |
| 02:18 ET | 255 | 0.82 |
| 02:21 ET | 720 | 0.82 |
| 02:56 ET | 3000 | 0.82 |
| 02:59 ET | 10225 | 0.81 |
| 03:01 ET | 6328 | 0.795 |
| 03:03 ET | 955 | 0.8044 |
| 03:06 ET | 1209 | 0.8 |
| 03:08 ET | 1379 | 0.804699 |
| 03:10 ET | 100 | 0.795 |
| 03:12 ET | 2799 | 0.79 |
| 03:17 ET | 200 | 0.8 |
| 03:19 ET | 150 | 0.796 |
| 03:21 ET | 400 | 0.79735 |
| 03:26 ET | 405 | 0.8047 |
| 03:32 ET | 180 | 0.804699 |
| 03:33 ET | 300 | 0.8001 |
| 03:35 ET | 113 | 0.8036 |
| 03:37 ET | 1149 | 0.8099 |
| 03:39 ET | 780 | 0.8 |
| 03:42 ET | 535 | 0.81 |
| 03:44 ET | 500 | 0.805 |
| 03:46 ET | 590 | 0.8077 |
| 03:48 ET | 442 | 0.79 |
| 03:50 ET | 280 | 0.79 |
| 03:51 ET | 9205 | 0.8205 |
| 03:53 ET | 951 | 0.79 |
| 03:55 ET | 500 | 0.8205 |
| 03:57 ET | 254 | 0.79 |
| 04:00 ET | 369 | 0.82 |
Jan 18, 2023
BRIEF-Sqz Biotechnologies Receives Notice Regarding Continued Listing Standards From The New York Stock Exchange, from 4:33PM ET on Wednesday Jan 18, 2023 by Thomson Reuters
4:33PM ET on Wednesday Jan 18, 2023 by Thomson ReutersSQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange, from 4:30PM ET on Wednesday Jan 18, 2023 by Business Wire
4:30PM ET on Wednesday Jan 18, 2023 by Business Wire
Jan 4, 2023
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ, from 1:15AM ET on Wednesday Jan 04, 2023 by PR Newswire
1:15AM ET on Wednesday Jan 04, 2023 by PR Newswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
SQZ Biotechnologies Co | 24.4M | -0.3x | --- |
Angion Biomedica Corp | 21.1M | -1.2x | --- |
CASI Pharmaceuticals Inc | 28.3M | -1.0x | --- |
Codiak BioSciences, Inc. | 25.3M | -1.0x | --- |
Harpoon Therapeutics Inc | 34.2M | -0.5x | --- |
Nabriva Therapeutics PLC | 4.7M | -0.1x | --- |
Company Information
SQZ Biotechnologies Company is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases, and other serious conditions. In oncology, it is developing cell therapy platforms that are based on directing tumor antigen-specific immune activation via engineered antigen presentation. It has three oncology candidates in clinical trials across its SQZ Antigen Presenting Cell (APC), SQZ enhanced APC (eAPC) and SQZ Activating Antigen Carrier (AAC), cell therapy platforms. In its autoimmune diseases portfolio, the Company is developing its SQZ Tolerizing Antigen Carrier (TAC), cell therapy platform to restore immune tolerance to self-antigens or other autoimmune disease-associated antigens that are central to disease pathogenesis. APC platform is focused on generating CD8+ T cell responses. SQZAPCs are created by ex vivo engineering of a patient's own peripheral blood mononuclear cells.
Contact Information
- Headquarters
- 200 Arsenal Yards Blvd, Suite 210WATERTOWN, MA, United States 02472
- Phone
- 617-758-8672
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Amy Schulman
- Director
- Howard Bernstein
- Chief People Officer
- David First
- General Counsel
- Lawrence Knopf
- Chief Medical Officer
- Marshelle Warren
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $24.4M |
|---|---|
Revenue (TTM) | $21.9M |
Shares Outstanding | 29.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.73 |
Book Value | $4.41 |
P/E Ratio | -0.3x |
Price/Sales (TTM) | 1.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -358.61% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
